{"brief_title": "Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure", "brief_summary": "To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in HIV-infected patients in renal failure receiving maintenance hemodialysis.", "condition": ["HIV Infections", "Kidney Failure, Chronic"], "intervention_type": ["Drug"], "intervention_name": ["Zidovudine"], "criteria": "Inclusion Criteria Patients must have: - A positive HIV antibody test (ELISA confirmed by Western blot). - Chronic renal failure managed by a stable hemodialysis regimen. - Acceptable hepatic function defined by specified lab values. - Life expectancy > 6 months. - Enrollment is limited to 9 chronic hemodialysis patients and 9 Continuous Ambulatory Peritoneal Dialysis (CAPD) patients. These patients must be stable in their ESRD treatment regimen before entry. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Active, serious opportunistic infections at the time of study entry. - Fever > 100 degrees F at study entry. - Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or > 6 loose stools per day accompanied by significant weight loss). Patients with the following are excluded: - Active, serious opportunistic infections at the time of study entry. - Fever > 100 degrees F at study entry. - Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or > 6 loose stools per day accompanied by significant weight loss). Prior Medication: Excluded within 2 weeks of study entry: - Any other experimental therapy. Drugs which cause significant bone marrow suppression. Rifampin or rifampin derivatives. Cytolytic chemotherapy. Drugs which cause significant hepatotoxicity. Excluded within 4 weeks of study entry: - Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2. Excluded within 8 weeks of study entry: - Other antiretroviral agents (e.g., zidovudine [AZT], suramin, ribavirin, HPA-23, foscarnet, dextran sulfate, disulfiram, ddA/ddC, or dideoxycytidine). Active drug or alcohol abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Renal Dialysis", "mesh_term": ["HIV Infections", "Renal Insufficiency", "Kidney Failure, Chronic", "Zidovudine"], "id": "NCT00002047"}